Summary Human papillomavirus (HPV) is the main risk factor for invasive cervical cancer. High risk ratios are found in cross-sectional data on HPV prevalence. The question raised is whether this present evidence is sufficient for making firm recommendations on HPV screening. A validated cervical cancer screening model was extended by adding HPV infection as a possible precursor of cervical intraepithelial neoplasia (CIN). Two widely different model quantifications were constructed so that both were compatible with the observed HPV risk ratios. One model assumed a much longer duration of HPV infection before progressing to CIN and a higher sensitivity of the HPV test than the other. In one version of the model, the calculated mortality reduction from HPV screening was higher and the (cost-)effectiveness was much better than for Pap smear screening. In the other version, outcomes were the opposite, although the cost-effectiveness of the combined HPV + cytology test was close to that of Pap smear screening. Although small follow-up studies and studies with limited strength of design suggest that HPV testing may well improve cervical cancer screening, only large longitudinal screening studies on the association between HPV infection and the development of neoplasias can give outcomes that would enable a firm conclusion to be made on the (cost-)effectiveness of HPV screening. Prospective studies should address women aged 30-60 years.
. This is much higher than can be explained by the life-time risk of developing cervical cancer in these countries. For example, in the Netherlands, the rate for high-risk HPV types in woman aged 30+ with normal cytology is around 4%, while the cumulative risk for invasive cervical cancer is around 1%; the risk in women aged 30+ with normal cytology is again much smaller. Therefore, only a fraction of the infections with high-risk HPV types will progress to cervical cancer.
The goal of this study was to incorporate the very high observed HPV-associated risk ratios in a cervical cancer screening model and to investigate the consequences for HPV screening as expressed in predicted mortality reduction, negative side-effects and costs. The outcome of the follow-up studies carried out to date have been incorporated in the model in so far that HPV infections were assumed to precede HPV-infected neoplasias. They were not used for the quantification of the model as these studies were small or interpretation in quantitative epidemiological terms was limited by their design. The possible impact, however, will be discussed. The present study focuses on the question of whether recommendations about HPV screening can already be made on the basis of the available data and, if not, what type of data will be required to decrease uncertainty.
MATERIALS AND METHODS
The data Test-positive GRefers to the numbering of the disease stages in Figure 1 .
on cytological material of the cervix from women with negative cytology are 4% in the Netherlands (Rozendaal et al, 1996) , 5.7% in Portland, Oregon, USA (Bauer et al, 1993) and 4.6% in Spain (Munoz et al, 1992) . PCR-based HPV-positive rates on cytological material of women with a histologically confirmed diagnosis of CIN are 71% in Spain and 54% in Colombia (de SanJose et al, 1994) , 75% in the USA (Morrison et al, 1991) , 72% in the UK (Cuzick, 1994) and 59% in the Netherlands (Gaarenstroom et al, 1994) . HPV rates are higher in high-grade than in low-grade lesions. Noting that the reported results are of the same order of magnitude, we summarized them by assuming 4% HPV positiveness in cytologically negative women and 67% in women with CIN. On the basis of the worldwide study on histological material of Bosch et al (1995) , we assumed that 95% of the invasive carcinomas were HPV infected, i.e. only 5% of invasive cervical cancers developed without being preceded by an HPV infection. In accordance with the results of the Dutch study (Melkert et al, 1993) , HPV-positive rates are assumed to be constant between 30 and 60 years of age.
The model
Here, the relationship between HPV and cervical cancer in a stochastic microsimulation screening model is described. HPV in the model represents high-risk HPV types (16, 18, 31, 33, 35, 39, 45, (51) (52) 54, 56, (58) (59) 66, 68] . As shown in Figure 1 UK, respectively, in 1978 -82 (Jensen et al, 1990 ) and 9.9 in the USA in 1985 (Parkin et al, 1993) ]. The incidence level however did not influence the comparison of screening strategies.
Two model versions
Because only cross-sectional HPV data were available for the quantification of the model, there was an identification problem for the parameters describing HPV infections. Test-positive rates in women screened for the first time are a result of incidence x duration x sensitivity. In view of this non-identifiability, we decided to construct two model quantifications that were contrasting in HPV-screening outcomes. We varied duration and sensitivity and adjusted the incidence level to the observed testpositive rates for HPV. The longer the duration of progressive (to CIN) HPV infections (stage HPVt't in Figure 1 ) and the higher the sensitivity of the HPV test, the more effective HPV screening will be in reducing cervical cancer mortality. In order to minimize the negative side-effects (i.e. follow-up of HPV-positive women who will not develop cervical neoplasia), it is favourable to assume a short duration of harmless (non-progressive) HPV infection (stage HPV [2] in Figure 1 ). In model quantification A (see Table 1 ), the extra duration of the detectable preclinical phase because of HPV detection was assumed to be 10 years. The assumed sensitivity for HPV was 100% at all stages. Long duration and high sensitivity made model version A very favourable for HPV screening. In version B of the model, the detectable preclinical phase was only 1 year longer than in Pap smear screening, and sensitivity for high-risk HPV types was considerably lower than in version A. In HPV-infected neoplasia stages, sensitivity of the HPV test was equal to the sensitivity of the Pap smear (80% in HPV-positive CIN and 87.5% in HPV-positive invasive cancer), and sensitivity was only 50% in HPV infections without neoplasia. Compared with model A, model B was very unfavourable for HPV screening. The consequences of 
Consequences of true-positive test results
In the simulation, women with only negative tests at screening had a future screening after the regular screening interval. Women with positive cytology were followed up and in true-positive cases this led to the detection of neoplasia. Women with a negative Pap smear and a positive HPV test were assumed to be followed up with HPV tests and Pap smears every 6 months. This follow-up stopped either when the HPV infection was cleared (after which women go back to screening) or when there was a transition of the HPV infection to HPV-infected CIN (the neoplasia is detected). Detected CIN was assumed to be managed so that no invasive cancer would develop. For the management of CIN (diagnosis, treatment and after treatment check-ups), we accounted for 4 years of follow-up. This was in accordance with current practice in the management of CIN, at least in the Netherlands (van Ballegooijen et al, 1995) .
Consequences of false-positive test results
Women with borderline (ASCUS) or low-grade abnormalities in their Pap smears in the Netherlands, and also in many other countries, are followed up with repeat smears. Some of these women have negative repeat smears and are referred back for routine screening. Women with higher-grade abnormalities in their Pap smears are referred to a gynaecologist. In a proportion of these women, no neoplasia is found. As the model was adjusted for histologically confirmed detection rates, these so called 'falsepositive' cytological outcomes have to be accounted for separately. We made the following assumptions:
* Five per cent of the screening smears generated two repeat smears in women that did not have neoplasia. * Five per 10 000 screened women without CIN were referred to the gynaecologist (PALGA, 1995).
The costs of screening In order to account for the costs and savings of early detection, the costs of screening, follow-up, diagnosis and treatment were considered ( The results of model version B, which was unfavourable for HPV screening, were quite different. Combined screening performed every 5 years yielded a slightly higher mortality reduction (80% vs 79%, it was predicted at 77% with 10-yearly combined screening) than screening with cytology every 3 years and was 63% more costly, resulting in 60% higher costs per lifeyear gained. The number of years in follow-up were 2.5 times higher, as were the number of years in follow-up per life-year gained. In the predictions for screening with the HPV test alone, even a 3-yearly interval did not result in a mortality reduction as high as with 3-yearly Pap smear screening (the 1 year extra detectable phase for which sensitivity is 50% is outbalanced by the 5% progressive lesions that are not detectable because they are HPV negative). Costs per life-year gained and years in follow-up per life-year gained were 1.8 and 2.6 times as high respectively. Based on the model version A calculations, a decision might be made to replace Pap smear screening with HPV screening with a longer interval. This would lead to a greater mortality reduction at lower costs in terms of resources and negative side-effects. However, the model version B calculations suggest that Pap smear screening should not be replaced by any of the studied HPV screening strategies; costs and negative side-effects increased, while prevention of mortality did not improve.
Sensitivity analyses
We also calculated the costs of HPV screening assuming that HPVpositive women with negative cytology would be followed up every 3 years instead of every 6 months. The resulting total costs of HPV screening were lower, in particular according to model B in which cost-effectiveness of the combined test was close to the cost-effectiveness of Pap smear screening. However, less intensive follow-up in HPV-positive women would, with current knowledge, not be an acceptable option.
Economies of scale play an important role in the costs of an HPV test. Our estimate was based on a situation with, on average, 12 000 PCRs per year per laboratory. If the testing was concentrated in fewer laboratories, the tests would become cheaper. Moreover, new developments can cause an increase or decrease in the costs of routine HPV tests. Therefore, calculations were repeated under the assumption that the laboratory costs per HPV test of 65 Dfl were less than one-third, i.e. 20 Dfl, or doubled to 130 Dfl. The total costs per test, including the 25 Dfl for carrying out the smear/scrape, consequently will be 45 Dfl and 155 Dfl, respectively, for the HPV test and 90 Dfl and 200 Dfl for the combined test (Pap smear + HPV test). In our basic calculations, a follow-up session for HPV-positive women was restricted to an HPV test and a Pap smear. We repeated the calculations with twice the costs per follow-up session (280 Dfl instead of 140 Dfl). This would be approximately the costs incurred when a colposcopy is added. The results are summarized in Table 5 . Options that were more cost-effective than 3-yearly Pap smear screening remained more cost-effective and those that were less cost-effective also remained less cost-effective. The conclusions were, therefore, not affected by considerable changes in the assumptions about the costs of HPV screening.
DISCUSSION
We produced two model versions that both explained the high observed risk ratios for high-risk HPV types in women with cervical neoplasia compared with women with normal cytology. In addition, they were both compatible with the 'clearance' rates in repeated HPV tests observed in women with normal cytology. In model A, this clearance resulted from a short duration of harmless HPV infection. In model B, the low sensitivity of the HPV test explained why woman that were HPV positive at a first screening will often be HPV negative at the next one. The effects of HPV screening predicted by the two model versions widely differed. Hence, the high-risk ratios alone were inconclusive for the outcomes expected from HPV screening.
The first non-cross-sectional evidence for the crucial role of high-risk HPV infections for the development of cervical cancer has been found in observational follow-up studies. These studies show only progression to high-grade neoplasias in the presence of (persistent) HPV infection. This concerns women with normal (Rozendaal et al, 1996) and abnormal Remmink et al, 1995) cytology. Although these studies are very important for showing that HPV infection precedes the (progression of) neoplasia, they are too small (Rozendaal et al, 1996) or have an inadequate design Remmink et al, 1995) To explore the impact of longitudinal data, we simulated an observational cohort study with the two model versions A and B. In the simulation, women who entered the study with negative cytology have a Pap smear 5 years later. Predicted CIN detection rates in women who at entry were HPV negative and those who were HPV positive were discemed (Figure 2) . As the description of cervical neoplasia (CIN and invasive cervical cancer) of the model was the same in both model versions, the detection rate for CIN at Pap smear screening 5 years after negative cytology was the same. In version A, however, almost 70% of the women with histologically confirmed CIN (low and high grade) came from previously HPV-positive women, whereas in model version B this was only 20%. This reflects a higher predictive value for future CIN of a positive HPV test in version A. The fact that longitudinal outcomes clearly differ in both models means that different longitudinal outcomes can be consistent with present cross-sectional data and that, once such longitudinal data are available, at least one (and probably both) of models A and B can be rejected. The range of combinations of parameter values on duration of HPV infection and sensitivity of the HPV test that are compatible with observed data will strongly decrease, and better predictions can be made of results expected from HPV screening.
Although the cross-sectional data show a strong association between HPV and cervical neoplasia, the results are insufficient to arrive at recommendations on screening. The discussion, therefore, on the representativeness of the test-positive rates that we aimed at in our simulation (4% in cytologically negative women, 67% in women with CIN and from 83% to 95% in women with invasive cervical cancers) is premature. Nonetheless, it is interesting to assess the influence of lower or higher observed HPV test-positive rates. In women with invasive cancer, the higher the HPV positiveness, the better this will be for the effectiveness of HPV screening. Higher test-positive rates in women with normal cytology and in women with CIN, however, can only mean that more women who do not develop cervical cancer will be HPV positive (all women that will develop HPV-positive cervical cancer are already assumed to be HPV positive before the development of the cancer). These women will unnecessarily be detected and followed up, and the negative side-effects and cost of follow-up will increase. In other words, given that HPV infection precedes, for example, 95% of the progressive neoplasias, lower HPV prevalence in the cytologically negative women and in women with CIN implies less harmless and less costly HPV screening.
A modelling approach, as presented in this paper, is useful for a joint analysis of cross-sectional, longitudinal and other relevant epidemiological data. We will adjust our model as soon as new evidence becomes available.
Data from large PCR-based cohort studies will accumulate in the forthcoming years. The fact that many of them are solely focused on young women should be of major concern. The Copenhagen study (Kjear et al, 1996) is restricted to women under 30 years of age, and the median age of the women in the Portland study is 34 years (Bauer et al, 1993) . Screening for HPV in very young women would cause many women to be followed-up (because of the high prevalence in this age group of HPV infections that will clear) and is therefore not advisable. Moreover, the fact that prevalence is so much higher in younger age groups is also an expression of a different natural history of the HPV infection (at least a higher clearance rate) in this age group. Follow-up results from these women are obviously not transferable to the older age groups. Hence, further cohort studies should aim at women aged 30-60 years.
